AtaiBeckley reports positive results from Phase 2a social anxiety disorder trial
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) reported positive topline results from an exploratory Phase 2a trial evaluating its oral R-MDMA candidate,…
Browsing Tag